FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gary Remington

Research Profile

Chemicals & Drugs

Disorders

Activities & Behaviors

Schizophrenic Psychology

Concepts & Ideas

Procedures

Tomography, Emission-Computed

Co-author Network

Publications

TOP 3
Gagan Fervaha; Gary Remington
Neuroimaging findings in schizotypal personality disorder: a systematic review.
Melanie Dawn Guenette; Margaret Hahn; Loretta Lam; Tamara Arenovich; Araba Chintoh; Adria Giacca; Celine Teo; Gary Remington
Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model.
Aristotle N Voineskos; Bruce G Pollock; Tarek K Rajji; Gary Remington; Daniel Felsky; George Foussias; Jason Lerch; Nancy Lobaugh; Benoit H Mulsant
Neuroimaging evidence for the deficit subtype of schizophrenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gary Remington (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gagan Fervaha; Gary Remington
Neuroimaging findings in schizotypal personality disorder: a systematic review.
Progress in neuro-psychopharmacology & biological psychiatry 2013;43():96-107.
2013: Melanie Dawn Guenette; Margaret Hahn; Loretta Lam; Tamara Arenovich; Araba Chintoh; Adria Giacca; Celine Teo; Gary Remington
Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model.
Schizophrenia research 2013;146(1-3):162-9.
2013: Aristotle N Voineskos; Bruce G Pollock; Tarek K Rajji; Gary Remington; Daniel Felsky; George Foussias; Jason Lerch; Nancy Lobaugh; Benoit H Mulsant
Neuroimaging evidence for the deficit subtype of schizophrenia.
JAMA psychiatry (Chicago, Ill.) 2013;70(5):472-80.
2013: Gary Remington; Celine Teo; George Foussias; Margaret Hahn; Steve Mann; Ofer Agid
Examining levels of antipsychotic adherence to better understand nonadherence.
Journal of clinical psychopharmacology 2013;33(2):261-3.
2013: Gary Remington; Ofer Agid; George Foussias; Margaret Hahn; Naren Rao; Mark Sinyor
Clozapine's role in the treatment of first-episode schizophrenia.
The American journal of psychiatry 2013;170(2):146-51.
2013: Steve Mann; Jose Nobrega; Araba Chintoh; Paul Fletcher; Adria Giacca; Margaret Hahn; Gary Remington
Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition.
Pharmacology, biochemistry, and behavior 2013;103(4):717-22.
2013: Gary Remington; Ofer Agid; Larissa Ferguson; George Foussias; Krysta McDonald; Valerie Powell
Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?
Psychopharmacology 2013;225(3):505-18.
2013: Margaret K Hahn; Tony Cohn; Celine Teo; Gary Remington
Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.
Clinical schizophrenia & related psychoses 2013;6(4):186-96.
2012: Ofer Agid; George Foussias; Krysta McDonald; Cynthia Siu; Christopher Tsoutsoulas; Caroline Wass; Robert B Zipursky; Gary Remington
Happiness in first-episode schizophrenia.
Schizophrenia research 2012;141(1):98-103.
2012: Zeynep Yilmaz; Clement Zai; Tamara Arenovich; Rudi Hwang; Steve Mann; Gary Remington; Zafiris J Daskalakis
Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis.
Schizophrenia research 2012;140(1-3):214-20.
2012: Philip Seeman; Gary Remington
Antipsychotic dosing: extended, and transient.
Clinical schizophrenia & related psychoses 2012;6(2):86-7.
2012: Arun K Tiwari; A N Voineskos; Clement Zai; Jeffrey A Lieberman; Olga Likhodi; Herbert Y Meltzer; Daniel J Müller; Steven G Potkin; Gary Remington; James L Kennedy
Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia.
The pharmacogenomics journal 2012;12(3):260-6.
2012: Gagan Fervaha; Gary Remington
Interpreting a multivariate analysis of functional neuroimaging data.
Frontiers in psychiatry / Frontiers Research Foundation 2012;3():52.
2011: Mahesh Menon; Gary Remington; Taylor W Schmitz; Michele Korostil; David Mamo; Jean Addington; Adam K Anderson; Philip Gerretsen; Ariel Graff-Guerrero; Shitij Kapur
Exploring the neural correlates of delusions of reference.
Biological psychiatry 2011;70(12):1127-33.
2011: Takefumi Suzuki; Hiroyuki Uchida; Ariel Graff-Guerrero; Tarek K Rajji; Gary Remington; David Mamo
Management of schizophrenia in late life with antipsychotic medications: a qualitative review.
Drugs & aging 2011;28(12):961-80.
2011: Takefumi Suzuki; Hiroyuki Uchida; Ariel Graff-Guerrero; Benoit H Mulsant; Tarek K Rajji; Gary Remington; David Mamo
Treatment resistant schizophrenia and response to antipsychotics: a review.
Schizophrenia research 2011;133(1-3):54-62.
2011: Gary Remington; José N Nobrega; Margaret Hahn; Steve Mann; Patrick McCormick; Sridhar Natesan
Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations.
Pharmacology, biochemistry, and behavior 2011;100(1):86-9.
2011: Ofer Agid; Tamara Arenovich; George Foussias; Shitij Kapur; Gautam Sajeev; Robert B Zipursky; Gary Remington
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
The Journal of clinical psychiatry 2011;72(11):1439-44.
2011: George Foussias; S Mann; Robert van Reekum; Konstantine K Zakzanis; Ofer Agid; Gary Remington
Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits.
Schizophrenia research 2011;132(1):24-7.
2011: Margaret Hahn; Loretta Lam; Steve Mann; Tamara Arenovich; Araba Chintoh; Tony Cohn; Paul Fletcher; Adria Giacca; Melanie Guenette; Tom Wolever; Li Xu; Gary Remington
Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model.
Schizophrenia research 2011;131(1-3):90-5.
2011: Romina Mizrahi; Gary Remington; Pablo Rusjan; Ivonne Suridjan; Alan A Wilson; Ofer Agid; Carol Borlido; Sylvain Houle; Shitij Kapur
Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO.
Schizophrenia research 2011;131(1-3):63-8.
2011: Gary Remington; Philip Seeman; Chekkera Shammi; Alan Feingold; Steve Mann; Shitij Kapur
"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.
The Journal of clinical psychiatry 2011;72(8):1042-8.
2011: Gary Remington; Ofer Agid; George Foussias
Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.
Expert review of neurotherapeutics 2011;11(4):589-607.
2011: Nabilah I Chowdhury; Gary Remington; James L Kennedy
Genetics of antipsychotic-induced side effects and agranulocytosis.
Current psychiatry reports 2011;13(2):156-65.
2011: Renan Souza; Daniela V F Rosa; Marco A Romano-Silva; Mei Zhen; Herbert Y Meltzer; Jeffrey A Lieberman; Gary Remington; James L Kennedy; Albert H C Wong
Lack of association of NALCN genetic variants with schizophrenia.
Psychiatry research 2011;185(3):450-2.
2011: Renan Souza; Aristotle N Voineskos; Jeffrey A Lieberman; Herbert Y Meltzer; Gary Remington; James L Kennedy
Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective.
Human psychopharmacology 2011;26(1):21-7.
2010: Sanjeev Sockalingam; Chekkera Shammi; Valerie Powell; Lucy Barker; Gary Remington
Determining rates of hepatitis C in a clozapine treated cohort.
Schizophrenia research 2010;124(1-3):86-90.
2010: Ofer Agid; George Foussias; Shayna Singh; Gary Remington
Where to position clozapine: re-examining the evidence.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2010;55(10):677-84.
2010: Renan Souza; Gary Remington; Nabilah I Chowdhury; Matthew K Lau; Aristotle N Voineskos; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2010;20(10):688-94.
2010: Ofer Agid; George Foussias; Gary Remington
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
Expert opinion on pharmacotherapy 2010;11(14):2301-17.
2010: Clement Zai; Arun K Tiwari; Daniel J Müller; Vincenzo De Luca; Takahiro Shinkai; Sajid Shaikh; Xingqun Ni; David Sibony; Aristotle N Voineskos; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Gary Remington; James L Kennedy
The catechol-O-methyl-transferase gene in tardive dyskinesia.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2010;11(6):803-12.
2010: Tarek K Rajji; Hiroyuki Uchida; Zahinoor Ismail; Wenzie Ng; David Mamo; Gary Remington; Bruce G Pollock; Benoit H Mulsant
Clozapine and global cognition in schizophrenia.
Journal of clinical psychopharmacology 2010;30(4):431-6.
2010: Margaret K Hahn; Tony Cohn; Gary Remington
Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
The Annals of pharmacotherapy 2010;44(7-8):1349-50; author reply 1350-1.
2010: Renan Souza; Vincenzo De Luca; Gary Remington; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy; Albert H C Wong
Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.
Psychopharmacology 2010;210(3):347-54.
2010: George Foussias; Gary Remington
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2010;55(3):117-25.
2010: George Foussias; Gary Remington
Negative symptoms in schizophrenia: avolition and Occam's razor.
Schizophrenia bulletin 2010;36(2):359-69.
2010: Gabriela Novak; Alexandra Gallo; Clement Zai; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Aristotle N Voineskos; Gary Remington; James L Kennedy; Daniel Levesque; Bernard Le Foll
Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia.
Psychiatric genetics 2010;20(1):39-43.
2010: Clement Zai; Arun K Tiwari; Vincenzo S Basile; Vincenzo De Luca; Daniel J Müller; Aristotle N Voineskos; Gary Remington; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; James L Kennedy
Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.
Progress in neuro-psychopharmacology & biological psychiatry 2010;34(1):50-6.
2010: Gary Remington; George Foussias; Ofer Agid
Progress in defining optimal treatment outcome in schizophrenia.
CNS drugs 2010;24(1):9-20.
2009: G Foussias; Steve Mann; Konstantine K Zakzanis; Robert van Reekum; Gary Remington
Motivational deficits as the central link to functioning in schizophrenia: a pilot study.
Schizophrenia research 2009;115(2-3):333-7.
2009: Sanjeev Sockalingam; Chekkera Shammi; Gary Remington
Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study.
The Journal of clinical psychiatry 2009;70(8):1114-9.
2009: Wenzie Ng; Hiroyuki Uchida; Zahinoor Ismail; David Mamo; Tarek K Rajji; Gary Remington; Beth A Sproule; Bruce G Pollock; Benoit H Mulsant; Robert R Bies
Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study.
Therapeutic drug monitoring 2009;31(3):360-6.
2009: Clement Zai; Arun K Tiwari; Vincenzo S Basile; Vincenzo De Luca; Daniel J Müller; Nicole King; A N Voineskos; Gary Remington; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; James L Kennedy
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
The pharmacogenomics journal 2009;9(3):168-74.
2009: Vincenzo De Luca; Renan Souza; Emanuella Viggiano; Clement Zai; Takahiro Shinkai; Jeffrey A Lieberman; Steven G Potkin; Herbert Y Meltzer; Gary Remington; James L Kennedy
MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis.
Schizophrenia research 2009;110(1-3):200-1.
2009: Clement Zai; Arun K Tiwari; Vincenzo De Luca; Daniel J Müller; Natalie Bulgin; Rudi Hwang; Gwyneth C Zai; Nicole King; Aristotle N Voineskos; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Gary Remington; James L Kennedy
Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2009;19(5):317-28.
2009: Araba F Chintoh; Steve W Mann; Loretta Lam; Adria Giacca; Paul Fletcher; Jose Nobrega; Gary Remington
Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model.
Schizophrenia research 2009;108(1-3):127-33.
2009: Sanjeev Sockalingam; Gary Remington
Review: insufficient evidence to guide use of drugs for clozapine induced hypersalivation.
Evidence-based mental health 2009;12(1):12.
2008: Clement Zai; Marco A Romano-Silva; Rudi Hwang; Gwyneth C Zai; Vincenzo Deluca; Daniel J Müller; Nicole King; Aristotle N Voineskos; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Gary Remington; James L Kennedy
Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia.
Schizophrenia research 2008;106(2-3):248-52.
2008: Araba F Chintoh; Steve W Mann; Loretta Lam; Carol Lam; Tony A Cohn; Paul Fletcher; Jose N Nobrega; Adria Giacca; Gary Remington
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
Journal of clinical psychopharmacology 2008;28(5):494-9.
2008: Ofer Agid; Shitij Kapur; Gary Remington
Emerging drugs for schizophrenia.
Expert opinion on emerging drugs 2008;13(3):479-95.
2008: Araba F Chintoh; Steve W Mann; Tony K T Lam; Adria Giacca; Gary Remington
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.
Schizophrenia research 2008;104(1-3):23-30.
2008: Romina Mizrahi; Jean Addington; Gary Remington; Shitij Kapur
Attribution style as a factor in psychosis and symptom resolution.
Schizophrenia research 2008;104(1-3):220-7.
2008: Hiroyuki Uchida; David Mamo; Shitij Kapur; Alain Labelle; Chekkera Shammi; Erik Mannaert; Steve W Mann; Gary Remington
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
The Journal of clinical psychiatry 2008;69(8):1281-6.
2008: Mary V Seeman; David Clodman; Gary Remington
Transient tardive dystonia: overview and case presentation.
Journal of psychiatric practice 2008;14(4):251-7.
2008: Gary Remington
Alterations of dopamine and serotonin transmission in schizophrenia.
Progress in brain research 2008;172():117-40.
2007: J Renou; Vincenzo De Luca; Clement Zai; Natalie Bulgin; Gary Remington; Herbert Y Meltzer; Jeffrey A Lieberman; B Le Foll; James L Kennedy
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia.
Molecular psychiatry 2007;12(12):1058-60.
2007: Clement Zai; Rudi Hwang; Vincenzo De Luca; Daniel J Müller; Nicole King; Gwyneth C Zai; Gary Remington; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; James L Kennedy
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2007;10(5):639-51.
2007: Clement Zai; Vincenzo De Luca; Rudi Hwang; A Voineskos; Daniel J Müller; Gary Remington; James L Kennedy
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.
Molecular psychiatry 2007;12(9):794-5.
2007: Ofer Agid; Gary Remington; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Early use of clozapine for poorly responding first-episode psychosis.
Journal of clinical psychopharmacology 2007;27(4):369-73.
2007: Sanjeev Sockalingam; Chekkera Shammi; Gary Remington
Clozapine-induced hypersalivation: a review of treatment strategies.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2007;52(6):377-84.
2007: Guy Faulkner; Tony Cohn; Gary Remington
Interventions to reduce weight gain in schizophrenia.
Schizophrenia bulletin 2007;33(3):654-6.
2007: Gary Remington
Tardive dyskinesia: eliminated, forgotten, or overshadowed?
Current opinion in psychiatry 2007;20(2):131-7.
2007: Gary Remington; Jean Kwon; April Collins; Dan Laporte; Steve Mann; Bruce Christensen
The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia.
Schizophrenia research 2007;90(1-3):229-37.
2007: Guy Faulkner; Tony Cohn; Gary Remington; Hyacinth Irving
Body mass index, waist circumference and quality of life in individuals with schizophrenia.
Schizophrenia research 2007;90(1-3):174-8.
2007: Guy Faulkner; Tony Cohn; Gary Remington
Interventions to reduce weight gain in schizophrenia.
Cochrane database of systematic reviews (Online) 2007;(1):CD005148.
2006: Huma Saeedi; Gary Remington; Bruce K Christensen
Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood.
Schizophrenia research 2006;85(1-3):222-31.
2006: Tony Cohn; Gary Remington; Robert B Zipursky; Azar Azad; Philip Connolly; Thomas M S Wolever
Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2006;51(6):382-6.
2006: Gary Remington; David Mamo; Alain Labelle; Jeffrey Reiss; Chekkera Shammi; Erik Mannaert; Steve Mann; Shitij Kapur
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
The American journal of psychiatry 2006;163(3):396-401.
2006: Guy Faulkner; Tony Cohn; Gary Remington
Validation of a physical activity assessment tool for individuals with schizophrenia.
Schizophrenia research 2006;82(2-3):225-31.
2006: Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Augmenting strategies in clozapine-resistant schizophrenia.
CNS drugs 2006;20(2):171.
2005: Gary Remington; Philip Seeman; Chekkera Shammi; Steve Mann; Shitij Kapur
"Extended" antipsychotic dosing: rationale and pilot data.
Journal of clinical psychopharmacology 2005;25(6):611-3.
2005: Takahiro Shinkai; Vincenzo De Luca; Rudi Hwang; Chima Matsumoto; Hiroko Hori; Osamu Ohmori; Gary Remington; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Jun Nakamura; James L Kennedy
Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia.
Neuroscience letters 2005;388(2):116-20.
2005: Gary Remington; Chekkera Shammi
Overstating the case about recovery?
Psychiatric services (Washington, D.C.) 2005;56(8):1022; author reply 1022-3.
2005: Gary Remington
Rational pharmacotherapy in early psychosis.
The British journal of psychiatry. Supplement 2005;48():s77-84.
2005: Gary Remington; Pierre Chue; Emmanuel Stip; Lili C Kopala; Todd A Girard; Bruce Christensen
The crossover approach to switching antipsychotics: what is the evidence?
Schizophrenia research 2005;76(2-3):267-72.
2005: Carmen Chung; Gary Remington
Predictors and markers of clozapine response.
Psychopharmacology 2005;179(2):317-35.
2005: Peter Turrone; Gary Remington; Shitij Kapur; José N Nobrega
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.
Biological psychiatry 2005;57(4):406-11.
2005: Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Augmentation strategies in clozapine-resistant schizophrenia.
CNS drugs 2005;19(10):843-72.
2004: Tony Cohn; Denis Prud'homme; David Streiner; Homa Kameh; Gary Remington
Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2004;49(11):753-60.
2004: Johannes Tauscher; Tabasum Hussain; Ofer Agid; Nicolaas P L G Verhoeff; Alan Wilson; Sylvain Houle; Gary Remington; Robert B Zipursky; Shitij Kapur
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
The American journal of psychiatry 2004;161(9):1620-5.
2004: Gary Remington; Chekkera Shammi
The use of pharmacotherapy in the prodrome of schizophrenia.
CNS spectrums 2004;9(8):579-86.
2004: David Mamo; Shitij Kapur; Chekkera Shammi; George Papatheodorou; Steve Mann; François Therrien; Gary Remington
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
The American journal of psychiatry 2004;161(5):818-25.
2004: David Mamo; Gary Remington; José N Nobrega; Doug Hussey; Raman Chirakal; Alan Wilson; Glen Baker; Sylvain Houle; Shitij Kapur
Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine.
Synapse (New York, N.Y.) 2004;52(2):153-62.
2003: Jimmy Jensen; Anthony R McIntosh; Adrian P Crawley; David J Mikulis; Gary Remington; Shitij Kapur
Direct activation of the ventral striatum in anticipation of aversive stimuli.
Neuron 2003;40(6):1251-7.
2003: Michael Kiang; Bruce K Christensen; Gary Remington; Shitij Kapur
Apathy in schizophrenia: clinical correlates and association with functional outcome.
Schizophrenia research 2003;63(1-2):79-88.
2003: Peter Turrone; Gary Remington; Shitij Kapur; José N Nobrega
Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(8):1433-9.
2003: Michael Kiang; Zafiris J Daskalakis; Bruce K Christensen; Gary Remington; Shitij Kapur
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.
Journal of psychiatry & neuroscience : JPN 2003;28(4):293-9.
2003: Gary Remington
Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.
Journal of psychiatry & neuroscience : JPN 2003;28(4):275-84.
2003: Peter Turrone; Gary Remington; Shitij Kapur; José N Nobrega
The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Psychopharmacology 2003;165(2):166-71.
2002: Carolyn Dewa; Gary Remington; Nathan Herrmann; Joan Fearnley; Paula Goering
How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience.
Clinical therapeutics 2002;24(9):1466-76.
2002: Gary Remington; Shitij Kapur
Review: amisulpride is effective and safe for schizophrenia.
Evidence-based mental health 2002;5(3):85.
2002: Peter Turrone; Gary Remington; José N Nobrega
The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?
Neuroscience and biobehavioral reviews 2002;26(3):361-80.
2002: Gary Remington
'Atypical' antipsychotics: where does ziprasidone fit?
Expert review of neurotherapeutics 2002;2(1):13-24.
2002: Johannes Tauscher; C Jones; Gary Remington; Robert B Zipursky; Shitij Kapur
Significant dissociation of brain and plasma kinetics with antipsychotics.
Molecular psychiatry 2002;7(3):317-21.
2002: Tony Cohn; Gary Remington; Homa Kameh
Hyperinsulinemia in psychiatric patients treated with olanzapine.
The Journal of clinical psychiatry 2002;63(1):75-6.
2002: Gideon Koren; Tony Cohn; David Chitayat; Bhushan Kapur; Gary Remington; Diane Myles Reid; Robert B Zipursky
Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants.
The American journal of psychiatry 2002;159(1):136-7.
2001: Shitij Kapur; Gary Remington
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.
Biological psychiatry 2001;50(11):873-83.
2001: Gary Remington; Leon Sloman; M Konstantareas; K Parker; R Gow
Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study.
Journal of clinical psychopharmacology 2001;21(4):440-4.
2001: Gary Remington; I Khramov
Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.
Progress in neuro-psychopharmacology & biological psychiatry 2001;25(2):363-9.
2001: Shitij Kapur; Gary Remington
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Annual review of medicine 2001;52():503-17.
2001: Gary Remington; Chekkera Shammi; R Sethna; R Lawrence
Antipsychotic dosing patterns for schizophrenia in three treatment settings.
Psychiatric services (Washington, D.C.) 2001;52(1):96-8.
2000: S Silvestri; Mary V Seeman; Juan C Negrete; Sylvain Houle; Chekkera Shammi; Gary Remington; Shitij Kapur; Robert B Zipursky; Alan Wilson; Bruce K Christensen; Philip Seeman
Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.
Psychopharmacology 2000;152(2):174-80.
2000: Shitij Kapur; Robert B Zipursky; C Jones; C S Shammi; Gary Remington; Philip Seeman
A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
Archives of general psychiatry 2000;57(6):553-9.
2000: Shitij Kapur; Marie-Louise G Wadenberg; Gary Remington
Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 2000;45(3):241-6.
2000: Shitij Kapur; Robert B Zipursky; C Jones; Gary Remington; Sylvain Houle
Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
The American journal of psychiatry 2000;157(4):514-20.
2000: S A Chong; Gary Remington; K Z Bezchlibnyk-Butler
Effect of clozapine on polypharmacy.
Psychiatric services (Washington, D.C.) 2000;51(2):250-2.
2000: Gary Remington; Shitij Kapur
Atypical antipsychotics: are some more atypical than others?
Psychopharmacology 2000;148(1):3-15.
1999: Gary Remington; S A Chong
Conventional versus novel antipsychotics: changing concepts and clinical implications.
Journal of psychiatry & neuroscience : JPN 1999;24(5):431-41.
1999: Gary Remington; S A Chong; Shitij Kapur
Distinguishing change in primary and secondary negative symptoms.
The American journal of psychiatry 1999;156(6):974-5.
1999: S A Chong; Gary Remington; C H Tan
Risperidone treatment of tardive dyskinesia and dystonia.
The Journal of clinical psychiatry 1999;60(5):340-1.
1999: S A Chong; Gary Remington
Plasma olanzapine and clinical response.
Journal of clinical psychopharmacology 1999;19(2):192-4.
1999: Shitij Kapur; Robert B Zipursky; Gary Remington
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
The American journal of psychiatry 1999;156(2):286-93.
1998: S A Chong; Gary Remington
Re: Sertraline-clozapine interaction.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1998;43(8):856-7.
1998: Gary Remington; Shitij Kapur; Robert B Zipursky
APA Practice Guideline for schizophrenia: risperidone equivalents. American Psychiatric Association.
The American journal of psychiatry 1998;155(9):1301-2.
1998: Shitij Kapur; Robert B Zipursky; Gary Remington; C Jones; Jean N DaSilva; Alan Wilson; Sylvain Houle
5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
The American journal of psychiatry 1998;155(7):921-8.
1998: Gary Remington; Shitij Kapur; Robert B Zipursky
The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study.
Journal of clinical psychopharmacology 1998;18(1):82-3.
1998: Gary Remington; Shitij Kapur; Robert B Zipursky
Pharmacotherapy of first-episode schizophrenia.
The British journal of psychiatry. Supplement 1998;172(33):66-70.
1998: S A Chong; Gary Remington
Ethnicity and clozapine metabolism.
The British journal of psychiatry : the journal of mental science 1998;172():97.
1997: Shitij Kapur; Robert B Zipursky; Gary Remington; C Jones; G McKay; Sylvain Houle
PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.
The American journal of psychiatry 1997;154(11):1525-9.
1997: A A Collins; Gary Remington; K Coulter; K Birkett
Insight, neurocognitive function and symptom clusters in chronic schizophrenia.
Schizophrenia research 1997;27(1):37-44.
1997: Chekkera Shammi; Gary Remington
Clozapine-induced necrotizing colitis.
Journal of clinical psychopharmacology 1997;17(3):230-2.
1997: L A Tugg; D Desai; P Prendergast; Gary Remington; K Reed; Robert B Zipursky
Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects.
Schizophrenia research 1997;25(1):71-8.
1997: Shitij Kapur; Robert B Zipursky; P Roy; C Jones; Gary Remington; K Reed; Sylvain Houle
The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study.
Psychopharmacology 1997;131(2):148-52.
1997: Gary Remington; P Prendergast; K Z Bezchlibnyk-Butler
Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1997;42(1):53-7.
1996: Shitij Kapur; Robert B Zipursky; C Jones; Gary Remington; Alan Wilson; Jean N DaSilva; Sylvain Houle
The D2 receptor occupancy profile of loxapine determined using PET.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;15(6):562-6.
1996: Shitij Kapur; Gary Remington; C Jones; A Wilson; Jean N DaSilva; Sylvain Houle; Robert B Zipursky
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
The American journal of psychiatry 1996;153(7):948-50.
1996: A A Collins; Gary Remington; K Coulter; K Birkett
Depression in schizophrenia: a comparison of three measures.
Schizophrenia research 1996;20(1-2):205-9.
1996: Gary Remington; D Addington; E J Collins; B D Jones; P Lalonde; D J MacCrimmon; G W MacEwan
Clozapine: current status and role in the pharmacotherapy of schizophrenia.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1996;41(3):161-6.
1996: Shitij Kapur; Gary Remington
Serotonin-dopamine interaction and its relevance to schizophrenia.
The American journal of psychiatry 1996;153(4):466-76.
1995: Shitij Kapur; Gary Remington; Robert B Zipursky; Alan Wilson; Sylvain Houle
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Life sciences 1995;57(10):PL103-7.
1994: Debbie Schachter; Irwin Kleinman; P Prendergast; Gary Remington; S Schertzer
The effect of psychopathology on the ability of schizophrenic patients to give informed consent.
The Journal of nervous and mental disease 1994;182(6):360-2.
1994: K Z Bezchlibnyk-Butler; Gary Remington
Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1994;39(2):74-84.
1993: D E Addington; B Jones; David Bloom; G Chouinard; Gary Remington; P Albright
Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study.
Clinical therapeutics 1993;15(5):917-26.
1993: Gary Remington
Clinical considerations in the use of risperidone.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1993;38 Suppl 3():S96-100.
1993: Gary Remington; L Fornazzari; R Sethna
Placebo response in refractory tardive akathisia.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1993;38(4):248-50.
1993: A Baskys; S Wang; Gary Remington; Martin Wojtowicz
Haloperidol and loxapine but not clozapine increase synaptic responses in the hippocampus.
European journal of pharmacology 1993;235(2-3):305-7.
1993: Gary Remington; P Prendergast; K Z Bezchlibnyk-Butler
Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1993;38(3):159-61.
1993: Gary Remington; B Pollock; G Voineskos; K Reed; K Coulter
Acutely psychotic patients receiving high-dose haloperidol therapy.
Journal of clinical psychopharmacology 1993;13(1):41-5.
1993: G Chouinard; B Jones; Gary Remington; David Bloom; D Addington; G W MacEwan; A Labelle; L Beauclair; W Arnott
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Journal of clinical psychopharmacology 1993;13(1):25-40.
1992: J Jeffries; K Bezchlibnyk-Butler; Gary Remington
Amenorrhea and galactorrhea associated with fluvoxamine in a loxapine-treated patient.
Journal of clinical psychopharmacology 1992;12(4):296-7.
1991: L Fornazzari; Masanori Ichise; Gary Remington; I Smith
Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.
Journal of psychiatry & neuroscience : JPN 1991;16(4):227-9.
1991: L Fornazzari; Gary Remington; J Jeffries
Akathisia, porphyria and low iron.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1991;36(7):548.
1991: Gary Remington; H Rosenblat
Spousal allegations of incest during transient psychotic episodes.
The British journal of psychiatry : the journal of mental science 1991;159():287-8.
1990: Gary Remington; G Voineskos; B Pollock; K Reed; K Coulter
Prevalence of neuroleptic-induced dystonia in mania and schizophrenia.
The American journal of psychiatry 1990;147(9):1231-3.
1990: Gary Remington; M Menuck; P Schmidt; S Legault
The remitting atypical psychoses: clinical and nosologic considerations.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1990;35(1):36-40.
1989: M Menuck; S Legault; P Schmidt; Gary Remington
The nosologic status of the remitting atypical psychoses.
Comprehensive psychiatry 1989;30(1):53-73.
1987: Gary Remington; K Bezchlibnyk-Butler
Ineffective sublingual lorazepam: considerations.
Journal of clinical psychopharmacology 1987;7(5):365-7.
1984: J Jeffries; Gary Remington; J Wilkins
The question of lithium/neuroleptic toxicity.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1984;29(7):601-4.